The first new Alzheimer’s drug since 2003 approved by FDA.

The approval came despite the advisory committee’s near-unanimous vote against it. “The ap­proval, how­ev­er, will do lit­tle to quell crit­i­cisms from the swath of Alzheimer’s re­searchers, bio­sta­tis­ti­cians, and clin­i­cians who have ar­gued that Bio­gen cher­ry-picked da­ta and failed to show con­vinc­ing ev­i­dence that the drug can slow pa­tients’ cog­ni­tive de­cline.” | learn more